Updat3
Search
Sign in

FDA opens pilot creating 'qualified research institutions' to speed IND reviews and human trials

Topic: technologyRegion: north americaUpdated: i2 outletsSources: 5Spectrum: Mostly CenterFiltered: Global (0/5)· Clear⏱ 2 min read
📰 Scored from 2 outletsacross 1 Left 1 Center How we score bias →
Story Summary
SITUATION
The U.S. Food and Drug Administration is opening applications for a pilot program that creates a network of "qualified research institutions" to help drugmakers develop and review Investigational New Drug application packages, shortening time to first-in-human trials.
Coveragetap to expand ▾
Spectrum: Mostly Center🌍Other: 2
Political Spectrum
Position is inferred from coverage mix.
i2 outlets · Center
Left
Center
Right
Left: 1
Center: 1
Right: 0
Geography Coverage
Distribution of where coverage is coming from.
i2 unique outlets · Dominant: Global
KEY FACTS
  • The FDA has opened applications for a pilot program to create a network of "qualified research institutions."
  • The network will partner with companies to develop and review Investigational New Drug (IND) application packages to shorten time before human testing.
  • The pilot was first announced in June as part of Operation TrialBlazer, a U.S. Department of Health and Human Services initiative.
HISTORICAL CONTEXT

The immediate backdrop is the post‑COVID regulatory push to speed clinical development after the pandemic exposed slow, fragmented starts to human trials: March 2020 saw the FDA issue guidance on conducting clinical trials during the COVID‑19 public‑health emergency, and the U.S. government launched Operation Warp Speed on May 15, 2020, to compress development timelines.

The structural roots include statutory and policy changes that predated the pandemic: the 21st Century Cures Act (signed December 13, 2016) expanded use of real‑world evidence and patient‑focused development; the Food and Drug Administration Safety and Innovation Act (FDASIA, enacted July 9, 2012) created modern expedited pathways such as Breakthrough Therapy designation; and the federal Right‑to‑Try law (enacted May 30, 2018) reflected political pressure to widen access.

Brief

The U.S. Food and Drug Administration is opening applications for a pilot program to create a network of “qualified research institutions” to speed drugmakers' ability to begin testing products in humans. The pilot, first announced in June as part of Operation TrialBlazer by the U.S.

Department of Health and Human Services, will have institutions partner with companies to develop and review Investigational New Drug application packages.

Sources
0 of 5 linked articles · Filter: Global